Can I find the new clear domestic reimbursement policy for dabrafenib?

Dabrafenib (Dabrafenib) is a kinase inhibitor primarily used to target the BRAF V600E mutation in multiple types of cancer. It is used to treat melanoma, non-small cell lung cancer, thyroid cancer, solid tumors and low-grade gliomas with BRAF V600 mutations. Dabrafenib capsules and tablets as an oral suspension may be taken orally twice daily, at least 1 hour before or 2 hours after meals.

The original drug of dabrafenib has been approved for marketing in China. Its generic name is dabrafenib mesylate capsules and is also sold under the trade name of Tefila/TAFINLAR. It has an effective clinical activity regimen and is well tolerated. Dabrafenib mesylate capsules have passed the relevant regulations of the National Medical Insurance Administration and entered the scope of Class B medical insurance. Reimbursement is limited to patients who meet the indications. Patients who do not meet the conditions can only purchase this drug at their own expense. Patients can check relevant policies on the website of the National Medical Products Administration, or consult at local medical insurance bureaus or hospitals.

The original drug of dabrafenib sold in China is relatively expensive, and the price of each box of 50mg*120 capsules may be around 10,000 yuan. The Turkish version of the original drug Dabrafenib sold overseas, Specifications 75mg*120 capsules, may cost around 10,000 per box (the price may fluctuate due to exchange rates). There are also relatively cheap generics of dabrafenib sold overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, Specifications produced by Laos Pharmaceutical Factory The price of 75mg*120 tablets per box may be more than 4,000 yuan (the price may fluctuate due to exchange rates).